Session » Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1553

An Analysis of Real-World Data on the Safety of Etanercept in Elderly Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1551

Anti-Drug Antibodies to Certolizumab Pegol Are Assiciated with Low Drug Levels and Reduced Clinical Response at 3 Months in Patients with Inflammatory Joint Diseases

9:00AM-11:00AM: Abstract Number: 1521

Anti-IL-6 Therapy Modulates Leptin in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1518

Baricitinib and Tofacitinib in Real Life – Does Obesity Impact Response to Janus Kinase Inhibitor Therapy in Rheumatoid Arthritis?

9:00AM-11:00AM: Abstract Number: 1526

Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib

9:00AM-11:00AM: Abstract Number: 1554

Cigarette Smoking Does Not Affect Treatment Response to Tofacitinib in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1534

Comparative Risk of Diabetes Mellitus in Rheumatoid Arthritis Patients Treated with Different Biologics- a Cohort Study

9:00AM-11:00AM: Abstract Number: 1549

Comparison of Adverse Events and Survival of Treatment in Patients with Rheumatoid Arthritis Receiving Combined Treatment of Methotrexate and Leflunomide Versus Those Receiving Biological Therapy

9:00AM-11:00AM: Abstract Number: 1530

CRP Changes during Bacterial Infections in Baricitinib-Treated Patients with RA

9:00AM-11:00AM: Abstract Number: 1520

DMARD Hepatotoxicity in Rheumatoid Arthritis and Its Association with the Surrogates of Metabolic Syndrome

9:00AM-11:00AM: Abstract Number: 1525

Effect of JAK-Inhibitor Versus Bdmards on Quality of Life in Rheumatoid Arthritis : A Meta Analysis of Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 1546

Efficacy and Safety of Corticosteroids in Rheumatoid Arthritis: Systematic Literature Review and Practical Recommendations

9:00AM-11:00AM: Abstract Number: 1513

Efficacy of Etanercept By Body Mass Index in Women and Men with Rheumatoid Arthritis: A Post Hoc Analysis of Three Randomized Trials

9:00AM-11:00AM: Abstract Number: 1535

Enhancing Patient Ability to Process and Use Information about Medication Risks and Benefits

9:00AM-11:00AM: Abstract Number: 1545

Exploring the Effects of Depressive Symptoms on the Efficacy of Sarilumab and Improvements in Health-Related Quality of Life

9:00AM-11:00AM: Abstract Number: 1548

Favorable Effect of Hydroxychloroquine in Patients with Rheumatoid Arthritis and Diabetes or Impaired Glucose Control

9:00AM-11:00AM: Abstract Number: 1537

Frequency and Duration of Early Non-Serious Adverse Events in Rheumatoid Arthritis Patients Treated with Tofacitinib 5 Mg Twice Daily As Monotherapy and Combination Therapy

9:00AM-11:00AM: Abstract Number: 1514

Impact of Comorbidity Burden and Obesity on the Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1532

Impact of Immunogenicity on Clinical Efficacy and Administration Related Reaction in TNF Inhibitors: A Pooled-Analysis from Three Biosimilar Studies in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1547

Impact of Obesity on Drug Survival of Tofacitinib in Patients with Rheumatoid Arthritis: Analysis from the Turkbio Registry

9:00AM-11:00AM: Abstract Number: 1550

Improvement of HbA1c in Patients with Rheumatoid Arthritis and Diabetes Type 2 during Treatment with Tocilizumab

9:00AM-11:00AM: Abstract Number: 1516

Infection Events in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim All-Case Post-Marketing Surveillance

9:00AM-11:00AM: Abstract Number: 1517

Integrated Safety Analysis across Phase 3 Clinical Studies Including the Controlled and Uncontrolled Periods for Intravenous Golimumab in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1529

Long-Term, Real-World Safety of Adalimumab in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1524

Malignancies and Serious Infections in Randomized Controlled Trials of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1515

Malignancy in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim Analysis of All-Case Post-Marketing Surveillance

9:00AM-11:00AM: Abstract Number: 1536

Mean Platelet Volume Changes with Baricitinib Indicate Reduced New Platelet Production in Baricitinib-Treated Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1538

Moderate Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1552

No Effect of Concomitant Glucocorticoid Therapy on Efficacy and Safety of Tocilizumab Monotherapy Found in Rheumatoid Arthritis Clinical Trials

9:00AM-11:00AM: Abstract Number: 1523

Pain Is Improved in Around 50% of Patients and Fatigue in 40% of Patients with Rheumatoid Arthritis Treated with Sarilumab in the Target, Mobility and Monarch Trials

9:00AM-11:00AM: Abstract Number: 1519

Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years

9:00AM-11:00AM: Abstract Number: 1542

Real-World Data from a Post-Approval Safety Surveillance Study of Tofacitinib Vs Biologic Dmards and Conventional Synthetic Dmards: Five-Year Results from a US-Based Rheumatoid Arthritis Registry

9:00AM-11:00AM: Abstract Number: 1512

Reduction in Power Doppler Ultrasound Score with Tocilizumab Treatment Associates with Improvement in the Protective Profile of HDL in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1539

Safety of Methotrexate and Leflunomide Combination Therapy in the Treatment of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1533

Simulating Population Disability Outcomes for Alternative Treatment Pathways in Patients with Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1543

The Efficacy, Safety and Adherence of Biologicbiological Disease-Modifying Anti Rheumatic Drugs, Infliximab, Tocilizumab and Abatacept, in Elderly Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1511

The Relationship between Lipid Profile Changes and Inflammation across the Phase 3 Sarilumab Rheumatoid Arthritis (RA) Developmental Program

9:00AM-11:00AM: Abstract Number: 1541

The Safety Profile of Iguratimod in Real Clinical Practice: Analysis of 491 Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1522

Time Dependent Effect of Biologic Therapy on Overall Survival in Patients with Rheumatoid Arthritis and Cancer

9:00AM-11:00AM: Abstract Number: 1527

Tofacitinib Improves Left Ventricular Mass and Cardiac Output in Rheumatoid Arthritis Patients with Chronic Heart Failure

9:00AM-11:00AM: Abstract Number: 1544

Tofacitinib Safety and Efficacy in the Treatment of Rheumatoid Arthritis in a Central/Eastern European Subpopulation

9:00AM-11:00AM: Abstract Number: 1531

Tofacitinib Show Similar Retention When Used with and without Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry

9:00AM-11:00AM: Abstract Number: 1528

Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 1540

Validation of Hepatic Fibrosis Markers in People with Rheumatoid Arthritis on Methotrexate

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].